Evaluation of three commercially-available chikungunya virus immunoglobulin G immunoassays

Bibliographic Data

ID14968579
AuthorsPablo M De Salazar (0000-0002-8096-2001, Caribbean Public Health Agency, Port of Spain, Trinidad and Tobago., corresponding author), Anne Marie Valadere (Caribbean Public Health Agency, Port of Spain, Trinidad and Tobago.), Christin H Goodman (0000-0002-6629-2005, Centers for Disease Control and Prevention), Barbara W Johnson (Centers for Disease Control and Prevention)
Year2017
Volume41
Pages1
Publication date2017-07-05
Open AccessYes
TypeARTICLE
VenueRevista Panamericana de Salud Pública (JOURNAL)
Journal identifiersISSN: 1020-4989 • E-ISSN: 1680-5348
PublisherPan American Health Organization (PUBLISHER • US)
DOI10.26633/rpsp.2017.62
PMID28902275
OpenAlexW2620964807
LanguageEN
References cited9

The emergence of chikungunya virus in the Americas means the affected population is at risk of developing severe, chronic, rheumatologic disease, even months after acute infection. Accurate diagnostic methods for past infections are essential for differential diagnosis and consequence management. This study evaluated three commercially-available chikungunya Immunoglobulin G immunoassays by comparing them to an in-house Enzyme-Linked ImmunoSorbent Assay conducted by the Centers for Disease Control and Prevention (Atlanta, Georgia, United States). Results showed sensitivity and specificity values ranging from 92.8% – 100% and 81.8% – 90.9%, respectively, with a significant number of false-positives ranging from 12.5% – 22%. These findings demonstrate the importance of evaluating commercial kits, especially regarding emerging infectious diseases whose medium and long-term impact on the population is unclear

Antibody · Chikungunya · Environmental health · Immunoassay · Immunoglobulin G · Population · Virus · Malaria Research and Control · Medicine · Mosquito-borne diseases and control · Viral Infections and Vectors · Immunology · Virology